Cerium-polyphenol network protects against AMD-associated RPE degeneration via blood-retinal barrier immunomodulation

Résumé fourni par la source

Age-related macular degeneration (AMD) remains difficult to treat due to the complex pathogenesis of retinal microenvironment (RME). In this study, we developed a cerium-rhein network encapsulated with polyvinylpyrrolidone (CRP NPs) to enhance biocompatibility. CRP NPs exhibited robust catalase (CAT)- and superoxide dismutase (SOD)-like activities and modulated the immune microenvironment within blood-retinal barrier (BRB). In vitro, CRP NPs protected ARPE-19 cells from NaIO 3 -induced damage and preserved BRB integrity by upregulating tight junction proteins and transepithelial electrical resistance (TEER). Mechanistic studies using RNA-seq, western blotting, and molecular docking revealed that rhein released from NPs inhibits the receptor for advanced glycation end products (RAGE) signaling pathway. Together with the reactive oxygen species (ROS)-scavenging activity of cerium (Ce 3+ / 4+ ), this effect contributed to the suppression of ferroptotic cell death and attenuates the “HMGB1-RAGE-ROS-ferroptosis-HMGB1” vicious cycle. Besides, CRP NPs shifted microglia from a pro-inflammatory activation to an anti-inflammatory phenotype by reducing the release of high mobility group box-1 protein (HMGB1) and calreticulin (CALR). This immunomodulation led to remodeling of the RME, as evidenced by reduced levels of IL-1β, IL-6, TNF-α, and COX2. In a NaIO 3 -induced dry AMD-like degeneration mouse model, treatment with CRP NPs significantly preserved RPE, improved visual function, and restored BRB integrity. Collectively, these findings demonstrate that CRP NPs present a multimodal therapeutic platform for AMD-like retinal degeneration, acting through immunomodulation of the RME and inhibition of ferroptosis in retinal pigment epithelium.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.